UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn. No per-share price was disclosed. The deal closes by end of Q2 2026, pending antitrust clearance.
It’s NRTX-1001 that UCB wants: a neuronal cell therapy in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy (mTLE). The therapy delivers GABA-producing cells via a single minimally invasive brain injection, aiming to rebalance neural circuits and reduce seizures. Phase 1/2 data presented in December showed up to an 89% median reduction in debilitating seizures at seven to 12 months post-administration. Primary study completion is June 2027.
Drug-resistant mTLE commands a premium in neurological M&A, and cell therapy in CNS is an even scarcer asset class. The up to $650m upfront on a Phase I/II asset is a strong bet. Paying that much upfront for an earlier-stage, single-dose cell therapy signals UCB sees NRTX-1001’s profile as differentiated enough to justify the risk before Phase II data.
The milestone structure is worth examining. At $500m in milestones against a $650m upfront, UCB isn’t forcing Neurona shareholders to carry all the clinical risk.
UCB has done this before
This is the second time UCB has bought into epilepsy this decade. In 2022, the Belgian pharma bought Zogenix for up to $1.9 billion and walked away with Fintepla, which generated €427 million ($501 million) in 2025 sales, up 30% year-on-year, and is approaching a potential label expansion into a third epileptic disorder. UCB’s epilepsy portfolio is led by Briviact, which earned €758 million ($890 million) in 2025, up 14%. By that measure, UCB knows how to turn epilepsy acquisitions into revenue.
UCB CEO Jean-Christophe Tellier called NRTX-1001 capable of “durable targeted repair of the nervous system following a single dose” — a high bar for a Phase 1/2 asset.
Against the grain on cell therapy
Takeda and Novo Nordisk both exited cell therapy in October 2025. UCB is betting the other direction. Gilead reaffirmed its commitment to the space this year, buying CAR T partner Arcellx for $7.8 billion. The deal drops into a busy M&A window: the second half of March alone logged roughly $30 billion in biopharma deal activity, with Neurocrine and Eli Lilly among the recent buyers.
Bank of America advised UCB; Centerview Partners advised Neurona. Covington & Burling handled legal for UCB, Wilson Sonsini for Neurona.
If the 89% seizure-reduction numbers don’t hold at scale, UCB paid $650 million to lead a modality two major players just left.
— Diana Kowalski